Prophylaxis in severe forms of von Willebrand's disease: Results from the von Willebrand Disease Prophylaxis Network (VWD PN)

Haemophilia

Volumn 19, Issue 1, 2013, Pages 76-81

  Abshire, T C ^a   Federici, A B ^b   Alvarez M T ^c   Bowen, J ^d   Carcao, M D ^e   Cox Gill, J ^f   Key, N S ^g   Kouides, P A ^h   Kurnik, K ⁱ   Lail, A E ^d   Leebeek, F W G ^j   Makris, M ^k   Mannucci, P M ^l   Winikoff, R ^m   Berntorp, E ⁿ  

^a Medical Sciences Institute   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d RHO INC   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h ROCHESTER GENERAL HOSPITAL   (United States)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

^l FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^m UNIVERSITY OF MONTREAL   (Canada)

ⁿ LUND UNIVERSITY   (Sweden)

more..

Author keywords

Bleeding rate; Epistaxis; Gastrointestinal bleeding; Joint bleeding; Prophylaxis; Severe VWD

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMARTHROSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84870998006     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02916.x     Document Type: Article

References (28)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
3. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39: 346-58.
4. Baronciani L, Federici AB, Eikenboom JCJ. Clinical, laboratory, and molecular markers of type 3 von Willebrand disease. In: Federici CAL AB, Berntorp EE, Lillicrap D, Montgomery RR eds. Von Willebrand Disease: Basic and Clinical Aspects. Oxford, UK: Wiley-Blackwell, 2011: 207-13.
5. Rodeghiero F, Castaman G. Von Willebrand disease: epidemiology. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing, 2005: 265-71.
6. De Wee EM, Mauser Bunschoten EP, vander Bom JG et al. Health related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.
7. De Wee EM, Fijnvandraat K, de Goede Bolder A et al. Impact of von Willebrand disease on health related quality of life in a pediatric population. J Thromb Haemost 2011; 9: 502-9.
8. Von Willebrand EA. Hereditär pseudo hemofili. Fin Läkaresällsk Handl 1926; 68: 87-112.
9. Nichols W, Hutlin M, James A, Manco-Johnson M, Montgomery R, Ortel T. The Diagnosis, Evaluation, and Management of von Willebrand Disease. (NIH Publication No. 08-5832). US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute, 2007: 1-112.
10. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
11. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
12. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16: S23.
13. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study. Haemophilia 2007; 13: 15-24.
14. Halimeh S, Krümpel A, Rott H et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Thromb Haemost 2011; 104: 984-9.
15. Berntorp E, Abshire T. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006; 4: 2511-2.
16. Fischer K, Bom J, Mauser Bunschoten E, Roosendaal G, Berg H. Effects of haemophilic arthropathy on health related quality of life and socio economic parameters. Haemophilia 2005; 11: 43-8.
17. Donfield S, Shapiro A, Gomperts E, Lynn H. Haemophilia related morbidity and quality of life. Haemophilia 2005; 11: 418.
18. Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: e105.
19. ® in patients with von Willebrand's disease: a prospective multi centre study. Haemophilia 2010; 16: 615-24.
20. Federici AB, Mannucci PM, Marco P. Von Willebrand factor in high purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report. Haemophilia 2008; 14: 133-9.
21. ®, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-30.
22. ®): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
23. Federici AB. Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF?. J Thromb Haemost 2008; 6: 1726-8.
24. Castillo R, Escolar G, Monteagudo J et al. Role for platelet von willebrand factor in supporting platelet vessel wall interactions in von willebrand disease. Am J Hematol 1989; 31: 153-8.
25. Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991; 77: 1901.
26. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130.
27. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
28. ®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-9.